UniQure Hemophilia B Gene Therapy AMT-061 Has Early Phase IIb Success

Early positive data from a Phase IIb dose-confirmation study showed AMT-061 achieved and sustained therapeutic levels of Factor IX (FIX) activity in all three participating patients at six weeks after a single administration of the investigational AAV5-based gene therapy.